Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PISOXO: PIPAC, SOX, and Olaparib for locally-invaded gastric cancer
NCT04410887Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in gastric cancer (GC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
olaparib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04410887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410887.